Jake Baker
@jakebakermd.bsky.social
ID doc at a community hospital in West Michigan, recovering MD/PhD (abramovitchlab, TB genetics and metabolism) with a soft spot for research, public health, and HIV.
5. There's a lot of chatter in my circles about the number needed to treat (NNT) from this figure. Here, the calculation for NNT used the overall 35% risk reduction and applied it to each subgroup, even though each subgroup has different risk reduction. Is this presentation of NNT legit stats-wise?
November 20, 2024 at 6:18 PM
5. There's a lot of chatter in my circles about the number needed to treat (NNT) from this figure. Here, the calculation for NNT used the overall 35% risk reduction and applied it to each subgroup, even though each subgroup has different risk reduction. Is this presentation of NNT legit stats-wise?
4. Only the subgroup of 5-10% risk showed stat sig benefit. Combined, for 0-5% risk, statin had no effect (1.8% vs 1.7%). Reduced MACE was largely driven by patients with > 5% risk, and statins already should be considered here HIV or not. Should this change how we view statins in low risk PLHIV?
November 20, 2024 at 6:18 PM
4. Only the subgroup of 5-10% risk showed stat sig benefit. Combined, for 0-5% risk, statin had no effect (1.8% vs 1.7%). Reduced MACE was largely driven by patients with > 5% risk, and statins already should be considered here HIV or not. Should this change how we view statins in low risk PLHIV?
1. First up, subgroups of Pooled Cohort Equations (PCE) can skew from the overall model. REPRIEVE carved out patients with elevated ASCVD risk but low LDL: a subgroup of the PCE. What is the MACE rate for this subgroup and is it underestimated in the PCE even for non-HIV?
November 20, 2024 at 6:18 PM
1. First up, subgroups of Pooled Cohort Equations (PCE) can skew from the overall model. REPRIEVE carved out patients with elevated ASCVD risk but low LDL: a subgroup of the PCE. What is the MACE rate for this subgroup and is it underestimated in the PCE even for non-HIV?